BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31160489)

  • 1. Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of β-catenin expression in lung squamous cell carcinoma.
    Wang D; Gao Y; Zhang Y; Wang L; Chen G
    Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31160489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy.
    Bi Y; Jiang Y; Li X; Hou G; Li K
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):499-505. PubMed ID: 33225417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Both glypican-3/Wnt/β-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinoma.
    Hu P; Ke C; Guo X; Ren P; Tong Y; Luo S; He Y; Wei Z; Cheng B; Li R; Luo J; Meng Z
    Dig Liver Dis; 2019 Jan; 51(1):120-126. PubMed ID: 30001951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFL7 promotes hepatocellular carcinoma cell proliferation and inhibits cell apoptosis through increasing CKS2 expression by activating Wnt/β-catenin signaling.
    Li Z; Xue TQ; Yang C; Wang YL; Zhu XL; Ni CF
    J Cell Biochem; 2018 Dec; 119(12):10327-10337. PubMed ID: 30129142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
    Lai JP; Oseini AM; Moser CD; Yu C; Elsawa SF; Hu C; Nakamura I; Han T; Aderca I; Isomoto H; Garrity-Park MM; Shire AM; Li J; Sanderson SO; Adjei AA; Fernandez-Zapico ME; Roberts LR
    Hepatology; 2010 Nov; 52(5):1680-9. PubMed ID: 20725905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
    Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
    FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of miR-610 promotes proliferation and tumorigenicity and activates Wnt/β-catenin signaling in human hepatocellular carcinoma.
    Zeng XC; Liu FQ; Yan R; Yi HM; Zhang T; Wang GY; Li Y; Jiang N
    Mol Cancer; 2014 Dec; 13():261. PubMed ID: 25491321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Loss of Immunohistochemical Expression of Glypican 3 in Oral Squamous Cell Carcinoma Play a Role in the Wnt/β-catenin Signaling Pathway?
    Jot K; Urs AB; Kumar P
    Appl Immunohistochem Mol Morphol; 2021 Oct; 29(9):693-699. PubMed ID: 34091531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role and mechanism of HIF-1α-mediated glypican-3 secretion in hypoxia-induced tumor progression in hepatocellular carcinoma.
    Wang P; Tong K; Li Y; Li X; Zhang Y; Gu J; Lei P; Yan S; Hu P
    Cell Signal; 2024 Feb; 114():111007. PubMed ID: 38081444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
    Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
    Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.
    Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G
    Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.
    Li N; Wei L; Liu X; Bai H; Ye Y; Li D; Li N; Baxa U; Wang Q; Lv L; Chen Y; Feng M; Lee B; Gao W; Ho M
    Hepatology; 2019 Oct; 70(4):1231-1245. PubMed ID: 30963603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1.
    Tian Z; Jiang H; Liu Y; Huang Y; Xiong X; Wu H; Dai X
    Exp Cell Res; 2016 May; 343(2):135-147. PubMed ID: 27090017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New tumor suppressor microRNAs target glypican-3 in human liver cancer.
    Cartier F; Indersie E; Lesjean S; Charpentier J; Hooks KB; Ghousein A; Desplat A; Dugot-Senant N; Trézéguet V; Sagliocco F; Hagedorn M; Grosset CF
    Oncotarget; 2017 Jun; 8(25):41211-41226. PubMed ID: 28476031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGAT1 is a novel transcriptional target of Wnt/β-catenin signaling pathway.
    Akiva I; Birgül Iyison N
    BMC Cancer; 2018 Jan; 18(1):60. PubMed ID: 29310626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP.
    Miao HL; Pan ZJ; Lei CJ; Wen JY; Li MY; Liu ZK; Qiu ZD; Lin MZ; Chen NP; Chen M
    J Cell Biochem; 2013 Mar; 114(3):625-31. PubMed ID: 23060277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA AC007271.3 promotes cell proliferation, invasion, migration and inhibits cell apoptosis of OSCC via the Wnt/β-catenin signaling pathway.
    Shao TR; Zheng ZN; Chen YC; Wu QQ; Huang GZ; Li F; Zeng WS; Lv XZ
    Life Sci; 2019 Dec; 239():117087. PubMed ID: 31759044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma.
    Li L; Jin R; Zhang X; Lv F; Liu L; Liu D; Liu K; Li N; Chen D
    Hepatology; 2012 Oct; 56(4):1380-90. PubMed ID: 22706665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SALL4 promotes the tumorigenicity of cervical cancer cells through activation of the Wnt/β-catenin pathway via CTNNB1.
    Chen M; Li L; Zheng PS
    Cancer Sci; 2019 Sep; 110(9):2794-2805. PubMed ID: 31336010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation.
    Liu H; Hu J; Wei R; Zhou L; Pan H; Zhu H; Huang M; Luo J; Xu W
    J Exp Clin Cancer Res; 2018 Sep; 37(1):229. PubMed ID: 30249289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.